Evoke Pharma to Report Third Quarter Results on November 9, 2022
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments...
COVID-19
Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia
– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On...
ProSomnus® Announces FDA 510(k) Clearance for ProSomnus EVO™ [PH] Sleep and Snore Device
Device expands ProSomnus’ suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered...
NRC Health Study Finds Trust in Local Hospitals and Health Systems Increased During the Pandemic
Trust in individual healthcare providers depends largely on patients’ language preferences U.S. counties where provider trust is highest and lowest...
Vaxxinity to Present at Upcoming Investor Conferences in November
DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late...
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve...
Nanox to Report Third Quarter 2022 Financial Results on November 10, 2022
NEVE ILAN, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its...
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and...
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN,...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage...
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a...
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to...
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook...
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and short-term investments as of September 30, 2022;...